NCT06667141 Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
| NCT ID | NCT06667141 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Acrivon Therapeutics |
| Condition | Specific Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-08 |
| Primary Completion | 2026-08-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 100 participants in total. It began in 2024-10-08 with a primary completion date of 2026-08-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Signed written informed consent. 2. Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors. 3. Must be willing to provide redacted pathology report. 4. Subjects should have received no more than 3 lines of systemic therapy for recurrent disease. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months. 6. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST v1.1. 7. Adequate organ functions. 8. Must have progressed after prior line of treatment. Exclusion Criteria (all participants): 1. Participants with known symptomatic brain metastases. 2. Participant had systemic therapy within 3 weeks prior to the first dose of study drug. 3. Participant had radiation therapy for curative intent within 4 weeks prior to the first dose of study drug. 4. Participant had palliative radiation therapy within 2 weeks prior to the first dose of study drug. 5. Women who are pregnant or lactating.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06667141 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Specific Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06667141 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06667141 currently recruiting?
Yes, NCT06667141 is actively recruiting participants. Contact the research team at ACR-2316ClinicalTrial@acrivon.com for enrollment information.
Where is the NCT06667141 trial being conducted?
This trial is being conducted at Phoenix, United States, Beverly Hills, United States, Newport Beach, United States, Denver, United States and 11 additional locations.
Who is sponsoring the NCT06667141 clinical trial?
NCT06667141 is sponsored by Acrivon Therapeutics. The trial plans to enroll 100 participants.